Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

A large body of evidence strongly suggests that the p53 tumor suppressor pathway is central in reducing cancer frequency in vertebrates. The protein product of the haploinsufficient mouse double minute 2 (MDM2) oncogene binds to and inhibits the p53 protein. Recent studies of human genetic variants...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Atwal, G, Kirchhoff, T, Bond, E, Montagna, M, Monagna, M, Menin, C, Bertorelle, R, Scaini, M, Bartel, F, Böhnke, A, Pempe, C, Gradhand, E, Hauptmann, S, Offit, K, Levine, A, Bond, G
Format:	Journal article
Sprog:	English
Udgivet:	2009

Lignende værker

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene (vol 106, pg 10236, 2009)
af: Atwal, G, et al.
Udgivet: (2009)

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 25 (10236-10241) DOI: 10.1073/pnas. 0901298106)
af: Atwal, G, et al.
Udgivet: (2009)

Haplotype structure and selection of the MDM2 oncogene in humans.
af: Atwal, G, et al.
Udgivet: (2007)

MDM2 SNP309 accelerates colorectal tumour formation in women.
af: Bond, G, et al.
Udgivet: (2006)

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.
af: Bond, G, et al.
Udgivet: (2006)

MDM2 is a central node in the p53 pathway: 12 years and counting.
af: Bond, G, et al.
Udgivet: (2005)

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect.
af: Bond, G, et al.
Udgivet: (2005)

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.
af: Arva, N, et al.
Udgivet: (2005)

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
af: Bond, G, et al.
Udgivet: (2004)

MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
af: Grochola, L, et al.
Udgivet: (2010)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
af: Venkatesh, Byrappa, et al.
Udgivet: (2016)

Oncogenes /
af: 311669 Cooper, Geoffrey M.
Udgivet: (1995)

Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas
af: Calvo-Vidal, M Nieves, et al.
Udgivet: (2021)

MDM2 splice variants in Oral Cancer
af: Sam, K.K., et al.
Udgivet: (2011)

The dual interactions of p53 with MDM2 and p300 : implications for the design of MDM2 inhibitors
af: Kannan, Srinivasaraghavan, et al.
Udgivet: (2020)

Modulators of the p53-MDM2 interaction : search for MDM2 interactors using structural guidance
af: Lin, Jianqing
Udgivet: (2014)

Mdm2 widens its repertoire.
af: Coutts, A, et al.
Udgivet: (2007)

THE OXFORD MDM-2 MAGNETIC SPECTROMETER
af: Pringle, D, et al.
Udgivet: (1986)

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays
af: Brown, Christopher J., et al.
Udgivet: (2015)

Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.
af: Grochola, L, et al.
Udgivet: (2009)

5 × 5 25 Gbit/s WDM-MDM
af: Fazea, Yousef, et al.
Udgivet: (2015)

5 × 5 25 Gbit/s WDM-MDM
af: Fazea, Yousef, et al.
Udgivet: (2017)

Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells
af: Mayr, Christine, et al.
Udgivet: (2012)

Abstract 3700: Association of the G/G-SNP309 variant in the mdm2 gene with earlier tumor onset in female renal cell carcinoma patients
af: Stoehr, C, et al.
Udgivet: (2016)

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2
af: Yadahalli, Shilpa, et al.
Udgivet: (2019)

FOCAL PLANE DETECTOR FOR THE OXFORD MDM-2 SPECTROMETER
af: Winfield, J, et al.
Udgivet: (1986)

Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
af: Bergamaschi, D, et al.
Udgivet: (2005)

Sex differences in oncogenic mutational processes
af: Li, CH, et al.
Udgivet: (2020)

Identification of an oncogenic RAB protein
af: Wheeler, D. B., et al.
Udgivet: (2017)

The genetics of the p53 pathway, apoptosis and cancer therapy.
af: Vazquez, A, et al.
Udgivet: (2008)

MDM2 functions as a timer reporting the length of mitosis
af: Fulcher, LJ, et al.
Udgivet: (2025)

Oncogenic drivers and development
af: Cruz Hernandez, D, et al.
Udgivet: (2019)

MDM2 and MDMX bind and stabilize the p53-related protein p73
af: Ongkeko, W, et al.
Udgivet: (1999)

Secure MDM-OFDM-Ro-FSO system using HG modes
af: Amphawan, Angela, et al.
Udgivet: (2015)

Secure MDM-OFDM-Ro-FSO system using HG modes
af: Amphawan, Angela, et al.
Udgivet: (2015)

p53 ubiquitination by Mdm2: a never ending tail?
af: Coutts, A, et al.
Udgivet: (2009)

Mdm2 targets the p53 transcription cofactor JMY for degradation.
af: Coutts, A, et al.
Udgivet: (2007)

C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer.
af: Albasri, A, et al.
Udgivet: (2009)

Oncogene-induced senescence in pituitary adenomas and carcinomas.
af: Alexandraki, K, et al.
Udgivet: (2012)

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.
af: El-Jawhari, J, et al.
Udgivet: (2014)